First-quarter IPO star Menlo Therapeutics plummets on disappointing trial results
April 09, 2018 at 14:51 PM EDT
The Redwood City biotech company's stock soared by as much as 134 percent and was one of the three best performing IPO stocks of the year. But it plunged to as much as 43 percent below its IPO price on Monday.
